Grace M Musiime1, Anna C Seale2,3, Sarah G Moxon3, Joy E Lawn3. 1. Gertrude's Children's Hospital, Nairobi, Kenya. 2. Department of Infectious Diseases Informatics, University College London, London, UK. 3. Centre for Maternal, Adolescent, Reproductive and Child Health (MARCH), and Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
Abstract
OBJECTIVES: To assess the risk of gentamicin toxicity and potential number of neonates exposed annually to this risk, through treatment with WHO-recommended first-line antibiotics (gentamicin with penicillin) for the 6.9 million neonates with possible serious bacterial infection (PSBI). METHODS: Systematic literature review and assessment of the evidence using Cochrane and GRADE criteria. Meta-analysis was undertaken for pooled estimates where appropriate. RESULTS: Eleven studies (946 neonates) were included (nine randomised controlled trials and two prospective cohort studies). Six trials reported consistently measured ototoxicity outcomes in neonates treated with gentamicin, and the pooled estimate for hearing loss was 3% (95% CI 0-7%). Nephrotoxicity could not be assessed due to variation in case definitions used. Estimates of the number of neonates potentially affected by gentamicin toxicity were not undertaken due to insufficient data. CONCLUSION: Given wider scale-up of outpatient-based and lower-level treatment of PSBI, improved data are essential to better assess the risks from neonatal gentamicin treatment without assessment of blood levels, to maximise benefit and reduce harm.
OBJECTIVES: To assess the risk of gentamicintoxicity and potential number of neonates exposed annually to this risk, through treatment with WHO-recommended first-line antibiotics (gentamicin with penicillin) for the 6.9 million neonates with possible serious bacterial infection (PSBI). METHODS: Systematic literature review and assessment of the evidence using Cochrane and GRADE criteria. Meta-analysis was undertaken for pooled estimates where appropriate. RESULTS: Eleven studies (946 neonates) were included (nine randomised controlled trials and two prospective cohort studies). Six trials reported consistently measured ototoxicity outcomes in neonates treated with gentamicin, and the pooled estimate for hearing loss was 3% (95% CI 0-7%). Nephrotoxicity could not be assessed due to variation in case definitions used. Estimates of the number of neonates potentially affected by gentamicintoxicity were not undertaken due to insufficient data. CONCLUSION: Given wider scale-up of outpatient-based and lower-level treatment of PSBI, improved data are essential to better assess the risks from neonatal gentamicin treatment without assessment of blood levels, to maximise benefit and reduce harm.
Authors: Rachel S Hayward; Jan Harding; Rob Molloy; Lucy Land; Kate Longcroft-Neal; David Moore; Jonathan D C Ross Journal: Br J Clin Pharmacol Date: 2017-11-03 Impact factor: 4.335
Authors: Jonathan A Abuga; Symon M Kariuki; Amina Abubakar; Christopher Nyundo; Samson M Kinyanjui; Michael Boele Van Hensbroek; Charles Rjc Newton Journal: Dev Med Child Neurol Date: 2021-09-18 Impact factor: 4.864
Authors: Aline Simen-Kapeu; Anna C Seale; Steve Wall; Christabel Nyange; Shamim A Qazi; Sarah G Moxon; Mark Young; Grace Liu; Gary L Darmstadt; Kim E Dickson; Joy E Lawn Journal: BMC Pregnancy Childbirth Date: 2015-09-11 Impact factor: 3.007
Authors: Divya S Varghese; Shama Parween; Mustafa T Ardah; Bright Starling Emerald; Suraiya A Ansari Journal: Stem Cells Int Date: 2017-09-24 Impact factor: 5.443
Authors: Aline Fuchs; Julia Bielicki; Shrey Mathur; Mike Sharland; Johannes N Van Den Anker Journal: Paediatr Int Child Health Date: 2018-11 Impact factor: 1.990
Authors: Aoife M Rodgers; Maelíosa T C McCrudden; Aaron J Courtenay; Mary-Carmel Kearney; Katherine L Edwards; Rebecca J Ingram; Jose Bengoechea; Ryan F Donnelly Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191